How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

Panelists discuss how viloxazine fits into both pediatric and adult ADHD treatment plans, especially as a non-stimulant option for patients with complex cases or concerns about stimulant side effects, while emphasizing flexible dosing and caregiver involvement.

Panelists discuss how recent clinical studies on viloxazine in children and adolescents demonstrated early symptom improvement, dose-dependent efficacy, and tolerability, with the most benefit seen at 400 mg in those aged 11 and under.

Long COVID presents complex symptoms without clear diagnostic criteria, challenging traditional medical understanding and emphasizing the need for compassionate care.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

Anna Ornstein, MD's legacy as a Holocaust survivor and humanitarian psychiatrist inspires reflection on societal issues and the importance of empathy in healing.

The debate over palliative psychiatry's role in advocating for psychiatric euthanasia continues, raising ethical concerns about mental health care and patient autonomy.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

This heartfelt tribute poem to Dr Jessica Obeysekare celebrates her passion, empathy, and dedication in both life and academia.

Panelists discuss the clinical and practical advantages of pitolisant for patients with frequent cataplexy and concerns about controlled substances, highlighting its dual efficacy, favorable safety profile, and flexible dosing as key features that support a patient-centered, stigma-conscious approach to narcolepsy care.

Panelists discuss the importance of shared decision-making in narcolepsy care, emphasizing structured conversations that explore patient goals, treatment preferences, and concerns—while navigating practical barriers like insurance—so that therapy selection is personalized and collaborative, often requiring a multimodal approach for optimal outcomes.

“Keep, ancient lands, your storied pomp!” cries she With silent lips. “Give me your tired, your poor, Your huddled masses yearning to breathe free, The wretched refuse of your teeming shore.

An interdisciplinary gathering at the 2025 virtual conference of the Society for Digital Mental Health heard presentations and panel discussions on digital therapeutics, along with reports of studies on the technology and outcomes by student and young researchers.

Let's look at the intersection of psychiatry and the afterlife, including the beliefs, research, and personal insights on reincarnation and purpose.

Explore the transformative power of self-compassion through poetry, mentorship, and shared humanity in overcoming doubt and anxiety.

H. Steven Moffic, MD, discusses social psychiatric connections to the Declaration of Independence with some psychiatric additions to life, liberty, and pursuit of happiness.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

Sara Robinson, DNP, RN, PMHNP-BC, provides insight on considerations surrounding prescribing psychiatric medications for perinatal patients.

Researchers analyze single-cell communication in brains of people with PTSD, uncovering genetic variations that could lead to new treatments for this complex disorder.

Explore essential insights and best practices in geriatric psychiatry in our July theme! Submit your insights, tips, and case studies centered on healthy aging for older adults.

These 2 compelling memoirs delve into the complexities of schizophrenia, showcasing resilience, friendship, and the impact of mental health.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.